LY686017

neurokinin 1 receptor (NK1R) antagonist, a possible therapy for alcoholism; structure in first source

Also Known As:

(2-chloro-phenyl)-(2-(5-pyridin-4-yl-1-(3,5-bistrifluoromethyl-benzyl)-1H-(1,2,3)triazol-4-yl)pyridin-3-yl)methanone

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

1.	Gehlert, Donald R: 2 articles (04/2011 - 02/2010)
2.	Gackenheimer, Susan L: 1 article (04/2011)
3.	Iyengar, Smriti: 1 article (02/2010)
4.	Kielbasa, William: 1 article (02/2010)
5.	Marek, Gerard: 1 article (02/2010)
6.	Mozley, David: 1 article (02/2010)
7.	Peng, Xiaomei: 1 article (02/2010)
8.	Tauscher, Johannes: 1 article (02/2010)
9.	Vandenhende, Francois: 1 article (02/2010)

1.	Alcoholism (Alcohol Abuse) 04/01/2011 - "In a recent study, we disclosed the potential for the NK-1 antagonist, LY686017, to treat alcoholism in a clinical population. "
2.	Social Phobia 02/01/2010 - "The clinical development of LY686017 included a PET study and a proof-of-concept in social anxiety disorder (SAD). " 02/01/2010 - "Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder."

1.	Neurokinin-1 Receptor Antagonists